Perth, June 5, 2008 (ABN Newswire) - Helicon Group (ASX:HCG) wishes to inform the market of the release of a third party research report, compiled by Money Cat Consulting, which focuses on the company's core competencies, business model and product acquisitions.

Helicon is a specialty pharmaceutical licensing and marketing company that takes proven proprietary products and drives their market growth in China, the world's fastest growing pharmaceutical market.

The report outlines Helicon's existing product portfolio of Recell(R), Collatamp(R) G, Volplex(R) and Medwrap(TM) Island Wound Dressing with Microban(R), its highly experienced Board and Management, alongside its business strategy that concentrates on high margin pharmaceuticals and a high end target market.

For the full report, in both English and Chinese, please view the link below.

http://abnnewswire.net/lnk/7SZN6MWH